Cargando…

Neutralisation sensitivity of the SARS-CoV-2 omicron BA.2.75 sublineage

Detalles Bibliográficos
Autores principales:	Gruell, Henning, Vanshylla, Kanika, Tober-Lau, Pinkus, Hillus, David, Sander, Leif Erik, Kurth, Florian, Klein, Florian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier Ltd. 2022
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448327/ https://www.ncbi.nlm.nih.gov/pubmed/36084664 http://dx.doi.org/10.1016/S1473-3099(22)00580-1

Ejemplares similares

Evasion of neutralising antibodies by omicron sublineage BA.2.75
por: Sheward, Daniel J, et al.
Publicado: (2022)

SARS-CoV-2 Omicron sublineages exhibit distinct antibody escape patterns
por: Gruell, Henning, et al.
Publicado: (2022)

mRNA booster immunization elicits potent neutralizing serum activity against the SARS-CoV-2 Omicron variant
por: Gruell, Henning, et al.
Publicado: (2022)

Durability of omicron-neutralising serum activity after mRNA booster immunisation in older adults
por: Vanshylla, Kanika, et al.
Publicado: (2022)

Lung cell entry, cell–cell fusion capacity, and neutralisation sensitivity of omicron sublineage BA.2.75
por: Arora, Prerna, et al.
Publicado: (2022)

Cross-Variant Neutralizing Serum Activity after SARS-CoV-2 Breakthrough Infections
por: Tober-Lau, Pinkus, et al.
Publicado: (2022)

Omicron sublineage BA.2.75.2 exhibits extensive escape from neutralising antibodies
por: Sheward, Daniel J, et al.
Publicado: (2022)

Comparative neutralisation profile of SARS-CoV-2 omicron subvariants BA.2.75 and BA.5
por: Tan, Chee-Wah, et al.
Publicado: (2022)

Evolving antibody evasion and receptor affinity of the Omicron BA.2.75 sublineage of SARS-CoV-2
por: Wang, Qian, et al.
Publicado: (2023)

Pausing methotrexate prevents impairment of Omicron BA.1 and BA.2 neutralisation after COVID-19 booster vaccination
por: Habermann, Elisa, et al.
Publicado: (2022)

Long-term immunogenicity of BNT162b2 vaccination in older people and younger health-care workers
por: Tober-Lau, Pinkus, et al.
Publicado: (2021)

Serum neutralisation of the SARS-CoV-2 omicron sublineage BA.2
por: Chen, Lin-Lei, et al.
Publicado: (2022)

Detection of the Omicron BA.2.75 subvariant in Japan
por: Hirotsu, Yosuke, et al.
Publicado: (2023)

Protection against Reinfection with the Omicron BA.2.75 Subvariant
por: Chemaitelly, Hiam, et al.
Publicado: (2023)

Omicron BA.2.75 variant is efficiently neutralised following BA.1 and BA.5 breakthrough infection in vaccinated individuals, Israel, June to September 2022
por: Atari, Nofar, et al.
Publicado: (2022)

Efficacy of Antiviral Agents against the Omicron Subvariant BA.2.75
por: Takashita, Emi, et al.
Publicado: (2022)

Characterization of the enhanced infectivity and antibody evasion of Omicron BA.2.75
por: Cao, Yunlong, et al.
Publicado: (2022)

Neutralization of Omicron Subvariant BA.2.75 after Bivalent Vaccination
por: Chalkias, Spyros, et al.
Publicado: (2022)

Low neutralisation of the omicron BA.2 sublineage in boosted individuals who had breakthrough infections
por: Karaba, Andrew H, et al.
Publicado: (2022)

Cases of BA.2.75 and recent BA.2.75.2 subvariant of Omicron are increasing in India: Is it alarming at the global level?
por: Chakraborty, Chiranjib, et al.
Publicado: (2022)

Antigenic characterization of the SARS-CoV-2 Omicron subvariant BA.2.75
por: Wang, Qian, et al.
Publicado: (2022)

Virological characteristics of the SARS-CoV-2 Omicron BA.2.75 variant
por: Saito, Akatsuki, et al.
Publicado: (2022)

Characterization of SARS-CoV-2 Omicron BA.2.75 clinical isolates
por: Uraki, Ryuta, et al.
Publicado: (2023)

Neutralization of Omicron BA.4/BA.5 and BA.2.75 by booster vaccination or BA.2 breakthrough infection sera
por: Wang, Xun, et al.
Publicado: (2022)

Knowing the new Omicron BA.2.75 variant (‘Centaurus’): A simulation study
por: Zappa, Martina, et al.
Publicado: (2022)

A delicate balance between antibody evasion and ACE2 affinity for Omicron BA.2.75
por: Huo, Jiandong, et al.
Publicado: (2023)

Neutralization of SARS-CoV-2 Omicron BA.2.75 after mRNA-1273 Vaccination
por: Shen, Xiaoying, et al.
Publicado: (2022)

Effect of hybrid immunity and bivalent booster vaccination on omicron sublineage neutralisation
por: Hoffmann, Markus, et al.
Publicado: (2023)

Analytical Sensitivity of Lateral Flow Devices against SARS-CoV-2 Omicron Subvariants BA.4, BA.5, and BA.2.75
por: Mackenzie, Charlene, et al.
Publicado: (2022)

First sequenced cases of Omicron BA.2 sublineage in Ecuador
por: Andrade-Molina, D.A., et al.
Publicado: (2023)

Genomic surveillance of SARS-CoV-2 upsurge in India due to Omicron sub-lineages BA.2.74, BA.2.75 and BA.2.76
por: Singh, Urvashi B., et al.
Publicado: (2023)

An imported human case with the SARS-CoV-2 Omicron subvariant BA.2.75 in Yunnan Province, China
por: Zhang, Meiling, et al.
Publicado: (2022)

Genomic architecture and evolutionary relationship of BA.2.75: A Centaurus subvariant of Omicron SARS-CoV-2
por: Basheer, Atia, et al.
Publicado: (2023)

Differential serum neutralisation of omicron sublineages in patients receiving prophylaxis with tixagevimab–cilgavimab
por: Solera, Javier T, et al.
Publicado: (2023)

Bivalent mRNA vaccine booster induces robust antibody immunity against Omicron lineages BA.2, BA.2.12.1, BA.2.75 and BA.5
por: Fang, Zhenhao, et al.
Publicado: (2022)

Results of contact tracing for SARS-CoV-2 Omicron sub-lineages (BA.4, BA.5, BA.2.75) and the household secondary attack risk
por: Yu, Mi, et al.
Publicado: (2023)

Additional mutations based on Omicron BA.2.75 mediate its further evasion from broadly neutralizing antibodies
por: Guo, Huimin, et al.
Publicado: (2023)

The effect of cilgavimab and neutralisation by vaccine-induced antibodies in emerging SARS-CoV-2 BA.4 and BA.5 sublineages
por: Arora, Prerna, et al.
Publicado: (2022)

Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
por: Hillus, David, et al.
Publicado: (2021)

Non-covalent cyclic peptides simultaneously targeting Mpro and NRP1 are highly effective against Omicron BA.2.75
por: Yin, Shengnan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_qejb4au25da7tgvtrs7l5jgp09